New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
10:25 EDTICPT, ICPT, GILD, GILD, GALT, GALTSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen provides a tech assessment, along with a discussion of the drug development for NASH (Non-Alcoholic Steatohepatitis) on an Analyst/Industry conference call to be held on January 21 at 11 am.
News For ICPT;GILD;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 13, 2014
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
12:00 EDTICPTKOLs say 'remains to be seen' if OCA can get accelerated approval, says Leerink
Subscribe for More Information
11:55 EDTICPTIntercept not part of talks with journals, says Deutsche Bank
Subscribe for More Information
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
November 11, 2014
16:14 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
November 10, 2014
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:20 EDTGILD, GALTOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTGALTGalectin Therapeutics GR-MD-02 Phase 1 trial meets primary endpoint
Subscribe for More Information
08:48 EDTGILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
08:14 EDTGALTGalectin Therapeutics reports Q3 EPS (17c), consensus (27c)
Subscribe for More Information
07:20 EDTGILDGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use